Abstract:The vascular endothelial growth factor receptor-2 kinases (VEGFR-2) expressed on tumor cells and vessels are attractive targets for cancer treatment. Potent inhibitors for the VEGFR-2 receptor are novel strategies to develop anti-cancer drugs. In this work, template ligand-based 3D-QSAR studies were performed on a series of benzoxazole derivatives toward different cell lines (HepG2, HCT-116 and MCF-7). Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques were used to generate 3D-QSAR models. Good predictability was derived for the optimal CoMFA models (HepG2: R-cv(2) = 0.509, R-pred(2) = 0.5128; HCT-116: R-cv(2) = 0.574, R-pred(2) = 0.5597; MCF-7: R-cv(2) = 0.568, R-pred(2) = 0.5057) and CoMSIA models (HepG2: R-cv(2) = 0.711, R-pred(2) = 0.6198; HCT-116: R-cv(2) = 0.531, R-pred(2) = 0.5804; MCF-7: R-cv(2) = 0.669, R-pred(2) = 0.6577). In addition, the contour maps derived from CoMFA and CoMSIA models were also generated to illustrate the relationship between different fields and the inhibitory activities. Moreover, molecular docking and molecular dynamics (MD) simulations were also conducted to understand the binding modes and the potential interactions between the receptor and the inhibitors. Some key residues (Leu35, Val43, Lys63, Leu84, Gly117, Leu180 and Asp191) were pointed out for stabilizing the inhibitors in the binding pocket. The binding free energies for the inhibitors agreed well with the experimental inhibitory activity and indicated that steric, electrostatic and hydrogen bond interactions are the main driving force for inhibitor-receptor binding. Overall, a good consistency between theoretical 3D-SQAR and molecular docking and MD simulation studies would provide directions for the design of new candidates, avoiding time-consuming and costly synthesis and biological evaluations. On the whole, the results derived from this study could expand the understanding of benzoxazole derivatives as anticancer agents and would be of great help in lead optimization for early drug discovery of highly potent anticancer activity targeting VEGFR-2.

Structure-activity relationships and molecular design of epoxyketone peptide proteasome inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Combined 3D-QSAR, Molecular Docking and Molecular Dynamics Study on Derivatives of Peptide Epoxyketone and Tyropeptin-Boronic Acid As Inhibitors Against the Β5 Subunit of Human 20S Proteasome

Covalent Docking Modelling-Based Discovery of Tripeptidyl Epoxyketone Proteasome Inhibitors Composed of Aliphatic-Heterocycles.

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

3D-QSAR Studies on Tripeptide Aldehyde Inhibitors of Proteasome Using CoMFA and CoMSIA Methods

Molecular Docking,3D-QSAR,and Molecular Design of Boronic Acid Derivatives of Tyropeptin Inhibitors of 20S Proteasome

Discovery of Novel Covalent Proteasome Inhibitors Through a Combination of Pharmacophore Screening, Covalent Docking, and Molecular Dynamics Simulations.

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Preparation and Biological Evaluation of Soluble Tetrapeptide Epoxyketone Proteasome Inhibitors.

Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity

Structure-based QSAR, Molecule Design and Bioassays of Protease-Activated Receptor 1 Inhibitors

<i>In silico</i> studies of a novel scaffold of benzoxazole derivatives as anticancer agents by 3D-QSAR, molecular docking and molecular dynamics simulations

A Combined Molecular Modeling Study On A Series Of Pyrazole/Isoxazole Based Human Hsp90 Alpha Inhibitors

QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors

A Combined Molecular Modeling Study on a Series of Pyrazole/isoxazole Based Human Hsp90α Inhibitors

3d-Qsar Studies Of Dihydropyrazole And Dihydropyrrole Derivatives As Inhibitors Of Human Mitotic Kinesin Eg5 Based On Molecular Docking

3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.

Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.